Podcasts about penn medicine

Send us Fan MailThe NICU is one of the loudest environments a newborn will ever experience, yet it is also where the most vulnerable infants spend their earliest, most developmentally critical days. In this Tech Tuesday episode, Ben and Daphna sit down with Gabby Daltoso and Sophie Ishiwari, co-founders of the Sonura Beanie. Their device tackles two pressing NICU challenges at once: harmful noise exposure and disrupted parental connection. By embedding a low-pass filtration system tuned to the acoustic environment of the womb into standard hospital beanies, Sonura attenuates high-frequency alarms while preserving the frequency of the human voice. Parents can also send recordings of songs, stories, and their heartbeat directly to their infant at the bedside. With a feasibility trial underway at Penn Medicine and the University of Pennsylvania President's Innovation Prize secured, Gabby and Sophie are just getting started.To learn more, visit www.sonuracare.comSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Neurosurgeon Christina Jackson, MD, and radiation-oncologist Emily Lebow, MD, offer their unique perspectives on recent advances in the surgical and radiotherapeutic management of meningioma, complicated, often recurrent tumors that rise in the meninges of the brain and spinal cord.  Learn more about Emily Lebow, MD 

8:05PM: El Niño has been making headlines lately as this year, we're in for a “Super” El Niño. What exactly does that mean, and how will it affect Massachusetts and beyond? Guest: Dr. Emily Becker, Research Associate Professor in the Department of Atmospheric Sciences at the University of Miami's Rosenstiel School of Marine and Atmospheric Studies 8:15PM: Local kids facing serious illness & disability take the field with college athletes at Boston College for Team IMPACT’s 4th annual Boston College Field Day this Sunday, May 3, from 2-4 PM. Guest: Maura Ambrose, Regional Executive Director, Northeast at Team IMPACT 8:30PM: It’s college graduation time, and today’s graduates will be setting off to pursue careers they’ve spent years preparing for. They believe they have it all figured out, but this year’s college graduates are expected to change careers at least 5 times. Why is this? Guest: Marcy Fitzgerald, author of the critically acclaimed new book, “Finding Your Space: A Permission Slip for High Achievers to Evolve, Pivot, and Thrive on Their Own Terms” 8:45PM: Nuclear medicine may just be the answer for many cancer patients. Nuclear medicine uses radioactive material, and doctors say it can be a lifesaver. With radiation exposure known for causing cancer and damaging DNA, how could it possibly heal? Guest: Dr. Phil Mulugeta, Clinical Director, Division of Nuclear Medicine Imaging and Therapy at Penn Medicine and Associate Professor of Clinical Radiology at Perelman School of Medicine, UPennSee omnystudio.com/listener for privacy information.

This episode recorded live at the Becker's 16th Annual Meeting features Kevin Mahoney, CEO of Penn Medicine at the University of Pennsylvania & Chris Collins, CEO of ECG Management Consultants, discussing how academic health systems can scale while maintaining true integration across clinical care, research, and education. They explore governance, physician alignment, and leadership approaches that balance empathy with execution to drive systemwide performance and patient-centered care. This episode is sponsored by ECG Management Consultants.

This episode features Nishaminy Kasbekar, BS, PharmD, Chief Pharmacy Officer at Penn Medicine. Here she discusses the importance of meeting patience where they are, making sure pharmacists are more integrated in the entire continuum of care, AI and automation in pharmacy, and more.

This episode features Nishaminy Kasbekar, BS, PharmD - Chief Pharmacy Officer, Penn Medicine. Here she discusses the importance of meeting patience where they are, making sure pharmacists are more integrated in the entire continuum of care, AI and automation in pharmacy, and more.

What can the DNA of Neanderthals, woolly mammoths, and ancient proteins tell us about the future of medicine? In this episode, Professor César de la Fuente sits down to discuss his fascinating research goal: using the power of machines to accelerate discoveries in biology and medicine… This conversation explores: The growing global health threat of antimicrobial resistance (AMR). Why ancient DNA and extinct organisms may hold clues for next-generation antibiotics. The role that AI plays in uncovering the genetic data of extinct organisms. What the future of machine biology could mean for human health. Prof. de la Fuente is Presidential Associate Professor at the University of Pennsylvania, where he leads the Machine Biology Group. He is one of the youngest tenured professors in the history of Penn Medicine. He completed postdoctoral research at MIT and earned his PhD from the University of British Columbia. He is widely recognized for pioneering the first computer-designed antibiotic shown to be effective in animal models, which is an achievement that helped launch the emerging field of AI-driven antibiotic discovery. His lab has since identified more than one million potential antimicrobial compounds through computational biology. In addition, Prof. de la Fuente has delivered over 350 invited lectures worldwide, co-authored an influential book on machine learning for drug discovery, secured multiple patents, and published more than 180 peer-reviewed papers in leading journals, including Cell, Science, Nature Communications, PNAS, and Advanced Materials. You can follow Prof. de la Fuente's latest discoveries and research here!

Clinician-researcher Ravi K. Amaravadi, MD, recalls a time within recent memory when no therapies existed for Stage IV metastatic melanoma, and reflects upon the 17 FDA-approved therapies now available to treat the disease. In this podcast, Dr. Amaravadi notes that many of these agents— including molecularly targeted therapy, immunotherapy in solid tumors, TIL cellular therapy, and personalized mRNA cancer vaccines—were pioneered at Penn Medicine.  Learn more about Ravi K. Amaravadi, MD 

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are prescribed for weight loss, diabetes, and blood-sugar management. But as more people use them, patients are reporting a decrease in cravings for drugs and alcohol. Researchers are now investigating whether GLP-1s might be effective for treating alcohol and drug addiction.  How much do we know? What are the risks? And do these drugs tell us anything new about the biology of addiction? Host Flora Lichtman talks with neuroscientist Joseph Schacht, who is conducting a clinical trial on GLP-1s and alcohol use; and Sarah Carstens, addictions clinical director of Outpatient Services at Penn Medicine's Princeton House Behavioral Health. Guests: Dr. Joseph Schacht is the co-director of the Division of Addiction Science, Prevention, and Treatment at the University of Colorado Anschutz School of Medicine.  Sarah Carstens is the addictions clinical director of Outpatient Services at Penn Medicine's Princeton House Behavioral Health.  Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Drs. Lori Christ and Angela Lober delve into the complexities of caring for late preterm infants. They highlight what makes these babies unique and how early intervention and proper support from clinicians and parents can dramatically improve their health and development. Use this episode to learn about practical strategies, education points, and resources that can prepare you and your colleagues to care for and educate families with the best evidence-based care. A must listen for postpartum or NICU nurses caring for this population! Meet our guests: Lori Christ, MD Read More   Dr. Lori Christ is Associate Professor of Pediatrics and a neonatologist at the Children's Hospital of Philadelphia and Penn Medicine, working in both the NICU and newborn nursery. She has been recognized for excellence in clinical care and teaching, including the Faculty Teacher of the Year and the Penn Medicine Patient Advocacy Award. Dr. Christ oversees quality and patient safety initiatives for full term and preterm newborns, including reducing disparities in breastfeeding, guidelines for late preterm care, and promoting kangaroo care. She also mentors trainees with an interest in quality improvement, reducing disparities in healthcare, and health care innovation. Angela Lober, PhD, MPH, RN, IBCLC  Read More Dr. Angela Lober is Director of Research and Grants at AWHONN, where she advances nursing science to improve outcomes for women and families. A registered nurse and International Board Certified Lactation Consultant, she has delivered evidence-based care since 2001. With a PhD and experience as a Clinical Associate Professor, she is an active researcher and dedicated educator. Angela is a committed advocate for maternal-child health, engaging in professional and community efforts to support families. Through mentorship, scholarship, and advocacy, she works to strengthen the nursing profession and promote equitable care. Episode Resources AWHONN Late Preterm Infant Resources  AWHONN Newborn Warning Signs    The post The Complexities of Caring for Late Preterm Infants appeared first on AWHONN.

Baby KJ was a pioneer before he was even a year old.  Born in 2024 with a rare, life-threatening genetic mutation, Nicole and Kyle Muldoon's son is the world's first patient to receive successful personalized gene editing therapy.  Doctors at the Children's Hospital of Philadelphia (CHOP) and Penn Medicine collaborated to create a unique drug just for KJ, to treat his disorder known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first months of his life in the hospital, KJ's medical breakthrough came with his first dose in February 2025 when he was 6 months old.    Now, a busy toddler and youngest brother, KJ is a piece of medical history – and he just started to walk.    Join us in advancing awareness and understanding of rare diseases. Visit CNBC.com/Cures to access clips, resources, or to sign up for our weekly newsletter.    Learn more about rare disease – and what to do in a diagnosis – at  the National Organization for Rare Disorders: https://rarediseases.org/   Follow Becky Quick on X: @BeckyQuick   Please share your thoughts or rare disease story in the comments, and join us on The Path. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this week's Poll Hub, we take a closer look at where things stand with cancer in the United States. It's still one of the most widespread diseases in the country, but the story is more multi-dimensional than it used to be. Treatments have improved significantly, and people are living longer than before. At the same time, more people are being diagnosed, including younger individuals, raising important questions about what's driving that increase and how much we still don't fully understand. We also explore how cancer care is evolving. New treatments like targeted therapies and immunotherapy are making a real impact, and in some cases, cancer is becoming something people manage over time rather than something immediately life-threatening. However, cancer isn't just one disease. There are many different types, each with its own challenges and treatment approaches, depending on the patient. And even with all this progress, there are still major challenges. Cancer can shape a person's life long after treatment -- physically, emotionally, and financially. The cost of care, access to treatment, and long-term impacts all play a role in the patient experience. Joined by Dr. Thomas Blom of Princeton Medical Group and Penn Medicine, and host of Medical Insights with Dr. Thomas Blom, we talk through where things are improving, where challenges remain, and what the future of cancer care might look like. Listen to Medical Insights with Dr. Thomas Blom here: https://open.spotify.com/show/1dhkwZs6AQ20GlaSJJ5Tbn?si=baaeccba89b94df8

(00:00:00) Anthony (Tony) Tommasini is the former chief classical music critic for The New York Times, a role he held from 2000 until his retirement in 2021 after 24 years with the paper. A graduate of Yale University with a Doctorate of Musical Arts from Boston University, he is also an accomplished author of four books, including The Indispensable Composers. As a pianist, he recorded two albums of Virgil Thomson’s music with support from the National Endowment for the Arts. Tommasini recently wrote about Marian Anderson’s legacy for the New York Times, a piece that earned praise from Dr. Henry Louis Gates, Jr. In 2022, Gates and Penguin Press invited him to contribute to the “Significations” series. His upcoming book, Voice of a Century: The Life and Artistry of Marian Anderson, will be released by Penguin in September. (00:22:40) Stacey C. Peeples, Curator and Lead Archivist at Pennsylvania Hospital, is helping guide the hospital’s celebration of its 275th anniversary by overseeing the transformation of its historic Pine Building into a public museum. As America’s first chartered hospital, Pennsylvania Hospital will use the new museum—opening in May—to showcase exhibits that connect its rich medical history with Penn Medicine’s ongoing innovations in science and healthcare.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

A new center in Philadelphia will support people with Lynch Syndrome, an inherited genetic condition that puts them at high risk for colon, uterine and other cancers. Penn Medicine's King Center for Lynch Syndrome is one of few centers in the world dedicated to Lynch syndrome. Pennsylvania Attorney General Dave Sunday said last week he will continue a lawsuit against a music-industry giant. The move breaks with the Trump administration -- at a time when Democrats say Sunday hasn't challenged the White House enough. There's a new wrinkle in Pennsylvania’s plan to use more than $700 million to expand high-speed internet access across the commonwealth. Fifty-six thousand Pennsylvania households live in manufactured homes. And many are experiencing significant increases in their monthly rent payments for the lots on which those homes stand. That's why Governor Josh Shapiro visited a Berks County manufactured housing community last week to call for reform, to protect Pennsylvanians from rent spikes. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Hematologist-oncologist Colin Thomas, MD, and dermopathologist Jina Chung, MD, review the diagnosis and treatment of the T cell lymphomas, including  the nodal and extra nodal (cutaneous) variants, describe the journey from diagnosis to treatment for T cell lymphoma patients, clinical research ongoing and the coordinated effort at Penn Medicine and the Abramson Cancer Center to control these rare, complex, and resilient malignancies.  Learn more about Colin Thomas, MD Learn more about Jina Chung, MD

In today's episode, we sat down with Megan Kruse, MD; and Sophia O'Brien, MD. Dr Kruse is a breast medical oncologist at Cleveland Clinic in Ohio. Dr O'Brien is an assistant professor of clinical radiology in the Divisions of Nuclear Medicine and Breast Imaging, as well as the associate program director of the Diagnostic Radiology Residency, at Penn Medicine in Philadelphia, Pennsylvania.In our exclusive interview, Drs Kruse and O'Brien highlighted the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making, noting the unique role of 18F-fluoroestradiol (FES)–PET/CT in lobular breast cancer, how future evolutions of breast imaging may influence FES-PET/CT use, and the importance of strong collaborations between medical oncologists and nuclear medicine physicians.

In today's OncClub episode, we spoke with Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE, about a pragmatic real-world question in advanced urothelial carcinoma: Can upfront dose reduction of enfortumab vedotin-ejfv (Padcev) improve tolerability, particularly neuropathy and treatment interruption, without compromising clinical outcomes in patients with bladder cancer? Dr Sedhom is co-lead of Geriatric Oncology at the Penn Cancer Service Line; associate director of the Penn Center for Cancer Care Innovation; and clinical director of Medical Oncology, co-lead of Psychosocial Oncology Services, division chief of the Palliative Care Division, and a clinical assistant professor of medicine (hematology-oncology) at Penn Medicine Princeton Health in Plainsboro, New Jersey. Dr Chow is an internal medicine resident at Penn Medicine in Philadelphia, Pennsylvania. Dr Mamtani is section chief of Genitourinary Cancers at Penn Medicine and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania. 

Drs Nadia Dawn Ali and Scott Peslak examine the pathology of sickle cell disease, its variable effects, and recent advances in treatment, including stem cell therapies and other new FDA-approved regimens for the disease.

In this episode, we sit down with Dr. Jean Bennett, Professor Emeritus of Ophthalmology at Penn Medicine and a true pioneer in gene therapy research. Dr. Bennett led the team that developed the first FDA-approved gene therapy to treat inherited blindness, transforming the lives of patients with retinitis pigmentosa and other retinal diseases. Her groundbreaking work spans over three decades and has opened doors for gene therapy applications far beyond ophthalmology. Dr. Bennett shares her remarkable journey from a curious child in New Haven, Connecticut—who chose seeds over candy at age four—to becoming a world-renowned scientist. She opens up about the challenges she faced as a woman in science, including being advised to leave her field entirely when seeking tenure at Penn. With candor and humor, she discusses how mentorship from previous Girl Power Gurus guest, Dr. Virginia Lee, helped her persevere, the emotional eureka moment when blind dogs first regained their sight, and what it felt like to witness blind children see for the first time. Dr. Bennett also offers invaluable advice for young women pursuing STEM careers, emphasizing the importance of finding work you love, building collaborative teams, and never giving up on your dreams despite the obstacles. This is a must-listen for anyone interested in science, medicine, or the power of determination.

PART 2I n this episode, we're joined by Dr. Andrew Zhang, and we explore Lumbar Interbody fusion. We discuss indications, relevant anatomy, differences between ALIF, OLIF, XLIF, + much much more.   Dr. Zhang is a board-certified, dual fellowship-trained orthopaedic surgeon specializing in spine surgery. He has a clinical interest in treating complex spinal deformity in adult and pediatric patients, including scoliosis and kyphosis, as well as robotic surgery, minimally invasive techniques, and the latest technology such as endoscopic spine surgery. His patient-centered approach involves empowering patients by educating them on their individual spinal conditions and developing a specific evidence-based treatment plan together with them as if they were his own family members. Dr. Zhang also has a particular interest in teaching residents and medical students and is actively involved in several research studies. He has been published in numerous peer-reviewed scientific journals and textbooks, and he has presented posters and on podiums at several national and international conferences. Dr. Zhang earned dual undergraduate degrees in biology and economics with highest honors from The George Washington University and obtained his medical degree with distinction in research from the same institution. He completed his orthopaedic surgery residency at Louisiana State University. He then completed an advanced spine fellowship at Brown University, followed by additional spine training at Yale University and the Shriners Hospitals for Children in Philadelphia and Shreveport. Dr. Zhang completed a second fellowship in advanced adult and pediatric comprehensive spine surgery at New York-Presbyterian/Columbia University/Cornell University, training with the world's foremost experts in spine surgery. He served as an Assistant Attending and Postdoctoral Clinical Fellow at Columbia University's Vagelos College of Physicians and Surgeons as well as a Clinical Instructor of Orthopedic Surgery in Neurological Surgery at Weill Cornell Medical College. His higher education culminated in graduating with distinction from the Surgical Leadership Program at Harvard University. Prior to joining Penn Medicine, Dr. Zhang was the Chief of Adult and Pediatric Orthopaedic Spine Surgery, as well as an Assistant Professor and the Associate Program Director to the Orthopaedic Surgery Residency at Louisiana State University Health Sciences Center. Education and training Medical School: George Washington University Residency: Montefiore Medical Center Residency: Louisiana State University Hospital Fellowship: Brown University Fellowship: NewYork-Presbyterian/Columbia University Medical Center Fellowship: Harvard University Goal of episode: To develop a baseline knowledge of Lumbar Interbody Fusion In this episode, we cover a wide array of topics including: Lumbar interbody fusion vs posterolateral fusion indications for interbody fusion danger and surgical pearls for ALIF, OLIF, XLIF, PLIF pertininent lumbar spine surgical anatomy 

In this episode, we're joined by Dr. Andrew Zhang, and we explore Lumbar Interbody fusion. We discuss indications, relevant anatomy, differences between ALIF, OLIF, XLIF, + much much more.   Dr. Zhang is a board-certified, dual fellowship-trained orthopaedic surgeon specializing in spine surgery. He has a clinical interest in treating complex spinal deformity in adult and pediatric patients, including scoliosis and kyphosis, as well as robotic surgery, minimally invasive techniques, and the latest technology such as endoscopic spine surgery. His patient-centered approach involves empowering patients by educating them on their individual spinal conditions and developing a specific evidence-based treatment plan together with them as if they were his own family members. Dr. Zhang also has a particular interest in teaching residents and medical students and is actively involved in several research studies. He has been published in numerous peer-reviewed scientific journals and textbooks, and he has presented posters and on podiums at several national and international conferences. Dr. Zhang earned dual undergraduate degrees in biology and economics with highest honors from The George Washington University and obtained his medical degree with distinction in research from the same institution. He completed his orthopaedic surgery residency at Louisiana State University. He then completed an advanced spine fellowship at Brown University, followed by additional spine training at Yale University and the Shriners Hospitals for Children in Philadelphia and Shreveport. Dr. Zhang completed a second fellowship in advanced adult and pediatric comprehensive spine surgery at New York-Presbyterian/Columbia University/Cornell University, training with the world's foremost experts in spine surgery. He served as an Assistant Attending and Postdoctoral Clinical Fellow at Columbia University's Vagelos College of Physicians and Surgeons as well as a Clinical Instructor of Orthopedic Surgery in Neurological Surgery at Weill Cornell Medical College. His higher education culminated in graduating with distinction from the Surgical Leadership Program at Harvard University. Prior to joining Penn Medicine, Dr. Zhang was the Chief of Adult and Pediatric Orthopaedic Spine Surgery, as well as an Assistant Professor and the Associate Program Director to the Orthopaedic Surgery Residency at Louisiana State University Health Sciences Center. Education and training Medical School: George Washington University Residency: Montefiore Medical Center Residency: Louisiana State University Hospital Fellowship: Brown University Fellowship: NewYork-Presbyterian/Columbia University Medical Center Fellowship: Harvard University Goal of episode: To develop a baseline knowledge of Lumbar Interbody Fusion In this episode, we cover a wide array of topics including: Lumbar interbody fusion vs posterolateral fusion indications for interbody fusion danger and surgical pearls for ALIF, OLIF, XLIF, PLIF pertininent lumbar spine surgical anatomy 

This episode provides a new perspective on how modern surgical practice has been shaped by military surgical history and how history can provide surgeons with a deepened appreciation for the events that have transformed patient care. Colonel (Ret.) Jeremy W. Cannon, MD, SM, FACS, leads the discussion that includes a medical student, junior faculty member, and senior surgeon/historian. Dr. Cannon's guests are Gordon L. Telford, MD, FACS, Justin Barr, MD, PhD, and Karina Hiroshige.   HOST Colonel (Ret.) Jeremy W. Cannon, MD, SM, FACS, USAF Reserve, MC, trauma surgeon at Penn Medicine in Philadelphia and Past President of the Excelsior Surgical Society   GUESTS Gordon L. Telford, MD, FACS, retired general surgeon from the Medical College of Wisconsin, in Milwaukee   Justin Barr, MD, PhD, transplant and hepatobiliary surgeon at the Ochsner Clinic in New Orleans, LA   Karina Hiroshige, MD/MBA Candidate at the University of Rochester School of Medicine & Dentistry, NY, and Research Fellow in Trauma, Surgical Critical Care & Emergency Surgery at the University of Pennsylvania, Philadelphia   Talk about the podcast on social media using the hashtag #HouseofSurgery    

When David Fajgenbaum nearly died of Castleman disease for the fifth time, he decided to take fate into his own hands. Using his medical training, he searched for an existing drug that might save his life—and found one. Now his organization, Every Cure, is scaling the same approach to uncover hidden treatments for other diseases with no known cure. David and Claudia discussed: How Every Cure is using AI to test 75 million possible disease-drug combinations The perverse incentives that keep generic drug repurposing in the shadowsWhy the hardest part of innovation isn't discovery, it's getting proven treatments into clinical practiceRepurposing existing drugs makes so much sense. But as David points out, there's no market for it:“Once a drug is generic.. the price is going to plummet… And even if you were to double the sales of your drug because you found a new disease area, now you've gone from 1% to 2% of what you got before… So there's no incentive whatsoever for our system to find a new use for a generic drug. Zero incentive.”Relevant LinksLearn more about Every CureRead David's book Chasing My Cure: A Doctor's Race to Turn Hope Into ActionWatch David's TEDTalk Listen to David's Podcast interview with Adam GrantGet info on the Dada2 FoundationWatch a video on Matt Might's story About Our GuestDavid Fajgenbaum, MD, MBA, MSc, is co-Founder & President of Every Cure and a physician-scientist at the University of Pennsylvania, where he is one of the youngest faculty members ever to receive tenure at Penn Medicine. He is also the national bestselling author of Chasing My Cure: A Doctor's Race to Turn Hope Into Action, which is being adapted into a film by Forrest Gump producer Wendy Finerman. During medical school, Fajgenbaum discovered a treatment that saved his own life and founded the Castleman Disease Collaborative Network. He has advanced 13 more repurposed treatments for cancers and rare diseases and co-founded Every Cure to unlock more hidden cures from existing medicines which has received over $100M from ARPA-H and TED's Audacious Project. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA. One of the youngest recipients of multiple top NIH and FDA grants, Fajgenbaum has authored over 100 scientific papers in leading journals, including The New England Journal of...

In this episode, John P. Donohue, Vice President of Data and Technology Solutions at Penn Medicine, shares insights on navigating healthcare complexity, implementing AI and extended reality tools, and balancing intentional technology adoption with emerging opportunities. He also discusses the importance of lifelong learning, mentorship, and servant leadership in driving organizational success.

Listen to this powerful interview with Dr. David Fajgenbaum who has an incredible new memoir, "Chasing My Cure: A Doctor's Race to Turn Hope into Action". David's story is truly unique; it's a tale of learning to live, while dying: a universally relatable story about getting up and fighting back after life knocks you down.A former Georgetown quarterback nicknamed "The Beast," David Fajgenbaum was also a force in medical school, where he was known for his unmatched mental stamina. But things changed dramatically when he began suffering from inexplicable fatigue. In a matter of weeks, his organs were failing and he was read his last rites. Doctors were baffled over a condition they had yet to even diagnose; floating in and out of consciousness, Fajgenbaum prayed for the equivalent of a game day overtime: a second chance.Miraculously, Fajgenbaum survived, but only to endure repeated near-death relapses from what would eventually be identified as a form of Castleman disease—an extremely deadly and rare condition that acts like a cross between cancer and an autoimmune disorder. When he relapsed on the only drug in development and realized that the medical community was unlikely to make progress in time to save his life, Fajgenbaum turned his desperate hope for a cure into concrete action: between hospitalizations he studied his own charts and tested his own blood samples, looking for clues that could unlock a new treatment. With the help of family, friends and mentors, he also reached out to other Castleman disease patients and physicians, and eventually came up with an ambitious plan to crowdsource the most promising research questions and recruit world- class researchers to tackle them; instead of waiting for the scientific stars to align, he proposed to align them himself.More than five years later and now married to his college sweetheart, his hard work has paid off: a treatment that he identified has induced a tentative remission and his novel approach to collaborative scientific inquiry has become a blueprint for advancing rare disease research. His incredible story demonstrates the potency of hope, and what can happen when forces of determination, love, family, faith and serendipity collide.David Fajgenbaum, MD, MBA, MSc is one of the youngest individuals to be appointed to the faculty at Penn Medicine. Co- founder and executive director of the Castleman Disease Collaborative Network (CDCN) and an NIH-funded physician- scientist, he has dedicated his life to discovering new treatments and cures for deadly disorders like Castleman disease, which he was diagnosed with during medical school. He is in the top 1 percent youngest grant awardees of an R01, one of the most competitive and sought-after grants in all of biomedical research. Dr. Fajgenbaum has been recognized on the Forbes 30 Under 30 healthcare list, as a top healthcare leader by Becker's Hospital Review, and one of the youngest people ever elected as a Fellow of the College of Physicians of Philadelphia, the nation's oldest medical society. He was one of three recipients – including Vice President Joe Biden – of a 2016 Atlas Award from the World Affairs Council of Philadelphia. Order "Chasing My Cure" at bookstores nationwide or at http://www.chasingmycure.com/Business Leadership Series Intro and Outro music provided by Just Off Turner: https://music.apple.com/za/album/the-long-walk-back/268386576

En EEUU, la hija del exmandatario Joe Biden que salió de la presidencia humillado por Donald Trump debido a su sistucaión de salud, compartió en redes socailes que su padre de 82 años, terminó su tratamiento de radioterapia contra el cáncer de próstata. En un gesto simbólico, tocó la campana en el centro Penn Medicine de Filadelfia, una tradición entre pacientes oncológicos que superan esa etapa.

Beau Wangtrakuldee is the founder and CEO of AmorSui, a science-backed medical supply brand bringing innovation, safety, and sustainability to the $58B PPE industry. A former scientist turned entrepreneur, Beau is reimagining protective apparel with clean chemistry, circular materials, and design that finally puts the user first.After a lab accident exposed the flaws in traditional PPE, Beau built AmorSui to bridge the gap between safety, comfort, and sustainability: offering PFAS-free, recyclable, and biobased alternatives trusted by global brands like Thermo Fisher Scientific and Benco Dental.Whether you're building a mission-driven ecommerce brand or rethinking your product's lifecycle, Beau shares a masterclass in turning real-world problems into scalable innovation, proving that circular design and commercial growth can coexist.In This Conversation We Discuss:[00:30] Intro[01:01] Building comfort and safety into every product[01:46] Creating a business from personal experience[04:37] Designing products people actually reuse[06:10] Validating ideas through real user stories[08:12] Raising capital before manufacturing begins[08:47] Allocating funds beyond first production run[09:45] Navigating minimum order quantity realities[10:32] Launching pre-sales with finished prototypes[11:04] Stay updated with new episodes[11:14] Balancing safety standards with speed to market[12:37] Episode Sponsors: Electric Eye & Heatmap[15:18] Marketing through word-of-mouth momentum[17:01] Refining targeting through early experiments[19:00] Discovering growth through customer feedback[21:34] Testing demand before building logistics[23:17] Learning quickly by shipping imperfect products[24:09] Focusing every decision on the end userResources:Subscribe to Honest Ecommerce on YoutubeModern PPE brand that protects people and the planet amorsui.com/Follow Beau Wangtrakuldee linkedin.com/in/beauwangtrakuldeeSchedule an intro call with one of our experts electriceye.io/connectClear, real-time data built for ecommerce optimization heatmap.com/honestIf you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

When baby KJ was diagnosed with a rare metabolic disorder, the team at Children's Hospital of Philadelphia (CHOP) had a unique treatment option for him: a personalized gene editing therapy developed in collaboration with Penn Medicine. On this episode, Madeline speaks to CHOP geneticist Dr. Rebecca Ahrens-Nicklas, who describes how KJ's first-of-its-kind treatment was developed – and what this amazing breakthrough means for other patients. 

JCO PO author Dr. Bryson Katona at the University of Pennsylvania Perelman School of Medicine shares insights into his article, “Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium” Host Dr. Rafeh Naqash and Dr. Katona discuss how, given differing guidelines as well as lack of detail about how PC surveillance should be performed, approaches to PC surveillance across centers often differs. TRANSCRIPT Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, I am thrilled to be joined by Dr. Bryson Katona, Director of the Gastrointestinal Cancer Genetics Program and Director of the Lynch Syndrome Program at the Penn Medicine's Abramson Cancer Center, and also lead author of the JCO PO article entitled "Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection or PRECEDE Consortium." Bryson, thanks for joining us again. Dr. Bryson Katona: Well, thank you so much for having me. I appreciate the opportunity. Dr. Rafeh Naqash: It is exciting to see that this work will be presented concurrently with the upcoming CGA meeting. Dr. Bryson Katona: Yes, it has been a fantastic partnership between JCO PO and the CGA-IGC and their annual meeting. And for those who may not be familiar, the CGA-IGC is the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. It is basically a professional organization dedicated to individuals who have hereditary GI cancer risk and focusing on providing education, promoting research, and really bringing together providers in this space from not just throughout the US but from across the globe as well. Dr. Rafeh Naqash: That is exciting to hear the kind of work you guys are doing. These are definitely interesting, exciting things. Now, going to what you have published, it is an area that is very evolving in the space of cancer screening, cancer surveillance, especially for a very aggressive cancer such as pancreatic cancer. Could you tell us currently, what are the general consensus? I know there are a lot of differences between different guidelines or societies, but what are the some of the commonalities if we were to start there first for pancreas cancer screening? If you are not a GI oncologist, you may not be aware that there is something with regards to pancreas cancer screening. Could you give us an overview and a background on that? Dr. Bryson Katona: Yeah, I think that pancreatic cancer screening really is one of the most controversial areas of all cancer screening. Part of that controversy is just because all the guidelines, the many different guidelines that are out there, do not always match up with one another, which I think leads to a lot of confusion, not just for providers but for patients who are trying to go through this, and then also the insurance companies in trying to get these screening tests covered. You know, when we think about who is eligible for pancreatic cancer screening, you know, it is important that these are not average-risk individuals. So really, we are only offering screening to high-risk individuals. And those can include people that have a strong family history of pancreatic cancer without a germline genetic susceptibility that has been identified. And those individuals we refer to as having familial pancreatic cancer. And the other big cohort is those individuals that carry hereditary pancreatic cancer predisposition. These are due to cancer risk mutations in many different genes, including many of the breast cancer risk genes like BRCA1 and BRCA2, as well as ATM and PALB2, but then other genes such as the Lynch syndrome genes, and then some of the higher risk genes such as those leading to Peutz-Jeghers syndrome as well as FAM, which is due to CDKN2A mutations. Dr. Rafeh Naqash: Thank you for that. Again, another practical question, and this may or may not be exactly related to your specific topic here, but perhaps to some extent there might be an overlap. If I get a patient from a colleague, and I see people in the early-phase clinical trial setting, so many different tumors for novel drugs, and I find an individual with, let us say, lung cancer who has a pathogenic BRCA2, which is somatic, should I be worried about pancreas cancer screening in that individual? Or have we not met that threshold yet in that circumstance? Dr. Bryson Katona: A lot of times these variants or these genes that are associated with pancreatic cancer risk get picked up on the somatic tumor profiles. Now, you know, whether or not those are truly germline variants typically requires the next step of referring the patient for germline genetic testing. So you know, I would not screen or make any kind of screening choices based on a somatic variant alone, but nowadays germline testing is so easy, so efficient, and relatively cheap that it is easy enough to confirm whether or not these somatic hits are in fact just somatic or may confer some germline risk in addition. Dr. Rafeh Naqash: So from what I understand from what you have said, there is debate about it, but it is something that should be done or is important enough that you need to figure out a path moving forward. Was that one of the reasons why you performed this project through this very interesting consortium called the PRECEDE Consortium? Dr. Bryson Katona: Yeah, that was one of our main reasons for doing this. And for those who do not know about the PRECEDE Consortium, this is a very large international, multi-institutional organization really focused on reducing death and improving survival from pancreatic cancer, primarily through increased and more effective use of screening and early detection strategies. This is an international consortium. There are over 50 sites now with nearly 10,000 patients who are enrolled in the consortium. So it really is at this point the largest prospective study of individuals who are at high risk for pancreatic cancer who are undergoing screening. And you know, I think amongst all of us in the consortium, just amongst discussions between colleagues and then, you know, often times when I see patients that are transferring their care to Penn who maybe had their screening done in another center before, what we were realizing is that, you know, although we all do a lot of screening, it seems that people are doing it slightly differently. And it does not seem that there is a real consensus approach across all centers about how pancreatic cancer screening should really be done. And it is one thing if you are thinking comparing, okay, well, maybe in the US we do it differently than, you know, in Europe or in other locations, but even among centers within the United States, we were still seeing very large differences in how pancreatic cancer screening in high-risk individuals were done. And so that led us to really pursue this survey of pancreatic cancer screening practices across the PRECEDE Consortium. So for this survey, we actually have 57 centers who the survey was sent out to. As you know, surveys are oftentimes very difficult to get good response rates back on, but we were fortunate to have 54 of the 57, or 95% of the centers, actually get back to us about their screening practices for this particular project. Dr. Rafeh Naqash: That is good to know. I hope you did not have to use any kind of gift cards for people to respond to the survey. But nevertheless, you got the information that you needed. Could you tell us what are some of the common denominators that you did identify and some of the differences that you identified? From your perspective, it sounds like there is no established consensus guidelines. There are different societies that have different perspectives on it. So I am sure some of what you found will probably have implications in maybe creating some guidelines. Is that a fair statement? Dr. Bryson Katona: Definitely a fair statement, and we found some very interesting results. I think one important result is really just the heterogeneity in the consortium. And so even before we got into pancreatic cancer screening practices, we also, we were asking consortium sites, “At your particular site, who is the individual that is leading these in-depth discussions about pancreatic cancer screening?” And while about 50% of the sites had a gastroenterologist leading it, about a quarter of the sites had a medical oncologist, a quarter had a surgeon leading these discussions as well. And we also found heterogeneity in who is the physician or the provider actually ordering these screening tests, again, with multiple different specialties across the different sites. But really one of the main areas that we wanted to hone in and focus on was how the different pancreatic cancer screening guidelines were actually utilized in each of the particular centers. The biggest controversial area in the field is for the gene mutation carriers, whether or not we should be requiring that a family history of pancreatic cancer be present in order for those individuals to qualify for pancreatic cancer screening. And the reason that is so controversial, let us take an example of BRCA1 and BRCA2 carriers. Currently, if you look through the guidelines, NCCN and the ASGE guidelines recommend that really all BRCA2 carriers undergo pancreatic cancer screening regardless of whether or not there is a family history, starting at age 50. However, other guidelines such as the AGA guidelines, or the AGA Clinical Practice Statement, as well as guidelines from the CAPS consortium, do recommend that a family history of pancreatic cancer be present in order to qualify for screening. But then we have different things for other genes. So for BRCA1 carriers, in fact, it is the ASGE guidelines that recommend all BRCA1 and 2 carriers undergo screening, whereas NCCN and the other guidelines that are out there do not recommend those individuals undergo screening. Again, this huge heterogeneity in guidelines is quite striking. And so when we assessed all the sites in the PRECEDE Consortium, we found some really interesting results with respect to these particular genes. For BRCA2 carriers specifically, we found that about half of the sites required a family history for recommending pancreatic cancer screening, but about half of the sites would offer it to all BRCA2 carriers regardless of if there was a family history of pancreatic cancer screening. Rates for BRCA1, PALB2, and ATM carriers were a little bit lower, where about a third of sites would offer screening really regardless of whether or not there is a family history of pancreatic cancer. And for Lynch syndrome, those rates were very, very low, with only about 13% of sites offering screening to Lynch patients in the absence of a family history. But I think, you know, we are all in the same consortium, but there is still just a lot of heterogeneity in how our own individual practices are run. Dr. Rafeh Naqash: Definitely different thoughts, different practices. But from what you saw, did it matter as far as outcomes are concerned whether it was a gastroenterologist doing the screening, or it was a medical oncologist, or a geneticist? Or is it a combination of all of these that actually makes the most difference? Dr. Bryson Katona: So I think we do need to get some more information about specialty-specific screening preferences. We just had one response per site in this particular survey, and so I think we are going to need a larger sample size in order to get that data. But I think that is certainly possible that, you know, certain subspecialties may prefer, you know, screening more aggressively or not including family history. That is definitely a question that we will be asking in future studies. Dr. Rafeh Naqash: Definitely more gift cards that will be needed as well. Moving on to another aspect of the implications for early detection, from a breast cancer, colon cancer standpoint, there is health economics research that shows it saves cost in the bigger picture. Has there been anything for pancreas cancer where early detection, early identification, early treatment actually ends up saving a lot more versus detecting metastatic pancreas cancer later? Dr. Bryson Katona: It is a great question. And of course, for any screening modality, you know, we would ultimately want it to be a cost-effective measure. In pancreas cancer screening, the jury is still a little bit out about whether or not pancreas cancer screening is truly cost-effective or not. There have been several different studies that have assessed this. And I think in general, the thought is that it is a cost-effective endeavor. But I think most of these cost-effectiveness estimates are actually related to what is the risk of pancreatic cancer in the population you are studying. And so when you have very, very high-risk individuals that have over a 10% lifetime risk of pancreatic cancer, it is almost a certainty that pancreatic cancer screening is going to be cost-effective. However, you know, if you have, say for example, BRCA1 carriers where lifetime risk of pancreatic cancer may be less than 5%, likely around like 3%, those individuals, I think it is going to be a tougher sell to say that it is cost-effective. But as we get more data on pancreatic cancer screening, that will be a very important question to ask. And you know, when you mentioned how does it save money, our goal at least in pancreatic cancer screening is to really downstage pancreatic cancer at the time of diagnosis and allow someone to undergo, you know, ideally a curative-intent surgery. There is data out there showing that we can downstage the cancers, that survival after the time of diagnosis is substantially increased after detection in a pancreatic cancer screening program. But again, these are studies that are based on fairly small numbers of converters. And so I think we need more data in that space as well, which is one of the main questions that the PRECEDE Consortium is trying to answer with all of our prospective data. Dr. Rafeh Naqash: Excellent. Well, I hope we see more interesting, exciting work from the PRECEDE Consortium at meetings as well as as a publication in JCO PO. I would like to shift gears briefly for a minute or two, Bryson, to you as an individual, your career. How have you evolved over the last 5, 7 years? How did you end up doing cancer genetics? What were some of the lessons that you learned along the way and some of those that you would want to share with our listeners, especially trainees and early-career faculty? Dr. Bryson Katona: Just to give you and others listening a little bit of background, but I am a physician-scientist, gastroenterologist, but a physician-scientist. And so my clinical practice is exclusively focused on individuals with hereditary GI cancer risk. I run a basic science lab where we do a lot of studies in organoids and mouse models of these hereditary GI cancer risk syndromes. And then I also have a clinical research group where we do early-phase clinical trials and screening and early detection trials, again in these same individuals with hereditary GI cancer risk. I think probably the most important thing that kind of allowed me to get to this stage in my career where I am trying to, you know, essentially try to juggle all three of these balls at the same time is that I absolutely love what I do. And I am so incredibly interested in what I do. And I think for young individuals that are coming through the pipeline and going through training, you know, I mean, finding a specialty and a clinical niche where you truly just enjoy the work and you enjoy the patients and you enjoy your colleagues is by far the most important thing. I ended up getting into the hereditary GI cancer space because a lot of my work earlier on in my career during my PhD and then in my postdoc work in the lab really focused on colorectal cancer. And I thought that focusing on cancer genetics could allow me to really continue to think from the molecular side of things while simultaneously being a gastroenterologist and taking care of patients with hereditary cancer risk. Dr. Rafeh Naqash: Well, thank you so much for giving us a sneak peek of your journey and insights on what perhaps works best, especially when you love what you do. I think that is one of the most important reasons a work tries to keep you going and keep you interested, keep you passionate. So thank you again. Thank you for listening to JCO Precision Oncology Conversations. Do not forget to give us a rating or a review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

For decades, clinical trial recruitment has been the biggest challenge in the industry. Christine Senn, senior vice president of Site-Sponsor Innovation at Advarra, offers insights into why the struggle continues, such as delays in getting regulations updated after a quarter of a century, and how to overcome the deadlock in clinical trial recruitment that is tied to current obsolete marketing guidelines. Also, host Deborah Borfitz shares the latest on beta blockers, low dose aspirin lowering the risk of recurring colorectal cancer, repurposing drugs for breast cancer relapse prevention, remote participation research on why athletes and military members face higher ALS risk, and the first agentic AI platform for life sciences from Medable. Show Notes News Roundup Rethinking beta blockers Press release on the Mount Sinai website Subgroup analysis study in the European Heart Journal Aspirin lowers risk of colorectal cancer recurrence Study in The New England Journal of Medicine  CLEVER study to prevent breast cancer relapse Study in Nature Medicine News release on Penn Medicine website   Champion Insights ALS initiative News release on Answer ALS website Medable's Agent Studio Press release on the Medable website Disseminating research findings Systematic review in PLOS Medicine  Guest Christine Senn, Ph.D., senior vice president of site-sponsor innovation at Advarra The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

In this episode, Michele Volpe, Chief Operating Officer of the University of Pennsylvania Health System, shares how Penn Medicine is balancing operational efficiency, workforce strategy, and regional expansion. She highlights the organization's efforts to bring advanced therapies closer to communities while reinvesting in people and facilities to build a stronger future.

Are you owning your voice or still shrinking in rooms where you belong?In this episode of Career Gems for the Journey podcast, Leah C. Murphy sits down with Dawana Holmes, an accomplished leadership strategist and executive coach, for a conversation that speaks directly to anyone who's ever second-guessed their power.Dawana opens up about what it truly means to take up space as a woman, especially as a woman of color, in corporate and leadership settings. From dismantling the “be grateful to be here” mindset to challenging the ways we're taught to dim our light, this episode is a call to reclaim your brilliance without apology.

Few topics matter more to parents than the medical well-being of their children. We sit down with Brad Myer, MD, to learn from his decades of experience as a leading local pediatrician. The founder of All Star Pediatrics, in Exton, Pennsylvania, Brad spent almost two decades growing an independent medical group. In our conversation, Brad talks us through the buying the practice from Penn Medicine and growing it to serve thousands of families, while navigating the world of health insurance, and recruiting and retaining a top team around him. Now with the management of the practice behind him, Brad walks us through how he gives back to his local community through board leadership and volunteerism with a number of local organizations.OUR PARTNERSouthern Chester County Chamber of CommerceLINKSAll Star PediatricsWebsite: allstarpediatrics.comBrad Dyer on LinkedInAdditional OrganizationsChester County Food BankBetter Days AheadWest Chester Food CupboardPhoenixville Area Community Services (PACS)Community Volunteers in Medicine (CVIM)Phoenixville Free Clinic (Phoenixville Free Medical Clinic)Area HospitalsChildren's Hospital of Philadelphia (CHOP)Nemours Children's HealthPenn MedicineRelated EpisodesFighting Food Insecurity Locally with Andrea YoundtTranscriptThe full transcript will be posted on our website as soon as it is available.

How can genetic insights change the way we treat cancer?In this episode of the PQI Podcast, Dr. Soni Tuteja, Director of Pharmacogenomics at Penn Medicine, shares how her team put pharmacogenomic testing into practice — and the impact it's had on patients. She highlights findings from her Journal of Clinical Oncology article on DPYD and UGT1A1 testing in GI cancers, showing how pre-treatment testing helped reduce toxicities, guide dose adjustments, and support safer therapy.Listeners will also hear about:Practical strategies to expand and sustain pharmacogenetic testing in real-world settingsHow pharmacists can lead patient counseling and program implementationThe role of NCODA's Positive Quality Interventions (PQIs), like DPYD testing before fluoropyrimidine treatment, in helping teams deliver safer, more personalized care

Earlier this year, baby KJ became the first patient in the world to receive a personalized gene editing therapy, which was developed by a team at Children's Hospital of Philadelphia (CHOP) and Penn Medicine. In June, KJ went home after spending more than 300 days at CHOP. On this episode of Breaking Through, Madeline speaks to KJ's parents, Kyle and Nicole, about the treatment that changed KJ's life – and how he's doing today.

Validation of AHA PREVENT in healthcare populations| JACC Deep Dive In this JACC Deep Dive, JACC Editor in Chief Harlan M. Krumholz, MD, SM, explores a study led by Dr. Pradeep Natarajan that evaluates how well the new AHA PREVENT risk equations predict cardiovascular events across four major U.S. health systems. The study found wide variation in performance—PREVENT was well-calibrated at Penn Medicine but significantly underestimated risk at Mass General Brigham and Vanderbilt, particularly among women and minority groups. Reviewers praised the importance and rigor of the work but raised key questions about model calibration, fairness in outcome comparisons, and whether truly "plug-and-play" risk tools are realistic across diverse healthcare environments.

Join host Geoffrey Rubin, MD, MBA, FACR, for a candid and wide-ranging conversation with Mitchell D. Schnall, MD, PhD, FACR—Professor of Radiology and Senior Vice President for Data and Technology Solutions at Penn Medicine. A highly accomplished radiology researcher and leader, Dr. Schnall served for 12 years as Vice Chair for Research in the Department of Radiology at the University of Pennsylvania, followed by another 12 years as Chair. His national leadership includes serving as Chair of ACRIN and the ACR Commission on Research, as well as President of the Academy for Radiology and Biomedical Imaging Research. His research contributions have earned him election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. In this episode, Dr. Schnall reflects on his journey—from a curious kid with a ham radio license and an Ivy League gymnast to a nationally recognized leader in academic radiology. He shares how his background in physics and engineering shaped his hands-on approach to problem-solving, innovation, and leadership—including his early work developing MRI coils and his unexpected path into breast imaging research. Dr. Schnall also discusses lessons from his time leading Penn Radiology, his philosophy on team building and faculty development, and why embracing discomfort, trusting others, and taking smart risks are essential traits for effective leadership. With humility, clarity, and a touch of humor, Dr. Schnall offers valuable insights into the realities of leading in academic medicine, the importance of intellectual generosity, and the power of staying curious throughout one's career. Don't miss this thoughtful conversation with a leader who continues to shape the future of radiology—while never losing sight of the joy in figuring things out. Behind the Mic! Dr. Schnall and his wife have been married for 37 years. Together, they have a 32-year-old daughter, a 29-year-old son, and an 11-month-old granddaughter! When he's not working, Dr. Schnall loves to take things apart and put them back together. He is a serious “DIYer”, having renovated his own kitchen and multiple bathrooms at his home. He also enjoys riding his bicycle and eating spicey hot peppers!

The United States Supreme Court upheld a Tennessee law banning some gender-affirming care for minors, and 26 other states have passed similar laws. Here in Philadelphia, Penn Medicine recently announced that they will no longer provide gender-affirming surgeries for people under 19. To get a better understanding of why some people want or need these procedures, Racquel Williams listens to personal experiences from Jasper Liem, Executive Director of The Attic Youth Center; mothasistah, an Attic staff member and parent of a transman; Naiymah Sanchez, a trans woman who works for the ACLU of PA; and Dr. Avra Laarakker, Gender Affirming/Plastic & Reconstructive Surgeon with Jefferson Pride Care at Jefferson Einstein Hospital. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

If you're anything like me, you might find the process of what happens to patients when they visit a radiation oncologist somewhat mysterious. During my training, I didn't receive much education about radiation oncology, and I'm not entirely sure what some of the terms mean (hypofractionated means fewer sessions, right?). Well, today's podcast aims to clear up all these uncertainties. We've invited Anish Butala, the Chief of the Palliative Radiotherapy Service at Penn Medicine, and Emily Martin, a palliative care doctor and past president of the Society for Palliative Radiation Oncology (SPRO), to explain everything we should know about radiation oncology. Additionally, Evie Kalmar, who suggested today's topic, will join us as one of our guest hosts. Tune in and we will walk you through the patient's journey from the initial planning visit to the final treatment, discuss common indications like bone and brain metastases, hear about when to consider steroid therapy, and highlight radiation therapy emergencies.

In a medical first, a team at Children's Hospital of Philadelphia and Penn Medicine has successfully treated an infant diagnosed with a rare genetic disorder by using a customized CRISPR gene editing therapy. The work, led by Penn Medicine's Kiran Musunuru and CHOP's Rebecca Ahrens-Nicklas, points to the potential to use bespoke gene editing therapies to treat others with rare genetic diseases for which no available medicines exist. We spoke to P.J. Brooks, deputy director of the Office of Rare Disease Research at the National Institutes of Health's National Center for Advancing Translational Sciences, about the breakthrough treatment, how the researchers were able to move from diagnosis to treatment with great speed, and what it would take to scale such an approach.

New Jersey's primary election is on Tuesday, and the Democratic side of the governor race is packed. KYW's South Jersey Reporter Mike Dougherty looks at the candidates on both sides. Philadelphia City Council and Mayor Cherelle Parker agreed on a $6.8 billion budget. City Hall Bureau Chief Pat Loeb tells us what was approved. Plus, we have updates on a SEPTA line closing, Penn Medicine ending gender-affirming surgeries for people under 19, a bill targeting AI deepfakes, and local students gaining national praise. 00:00 Intro 02:00 The NJ governor race is anybody's game 07:01 What's in Philadelphia's new budget? 13:26 SEPTA's new GM, and Chestnut Hill East Line closes for the summer 19:04 The fight over gender-affirming care for youth 24:59 PA bill addresses AI deepfakes, despite Trump bill to prohibit state AI laws 31:08 Philadelphia students honored in C-SPAN's StudentCam competition Listen to The Week in Philly on KYW Newsradio every Saturday at 5am and 3pm, and Sunday at 3pm. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

The Rich Zeoli Show- Hour 4: 6:05pm- On Thursday, the Trump Administration threatened to withhold federal funding from several sanctuary cities—including Philadelphia, New York City, Los Angeles, and Chicago—if they don't comply with federal law enforcement authorities seeking to crackdown on illegal immigration and the deportation of dangerous migrants residing in the country unlawfully. 6:15pm- While appearing on CNN, White House Deputy Chief of Staff Stephen Miller absolutely destroyed host Pamela Brown when she attempted to downplay border security and the deportation of potentially dangerous migrants who entered the U.S. unlawfully. 6:30pm- Friday marked Elon Musk's last day leading the Department of Government Efficiency (DOGE). President Donald Trump praised Musk's work, highlighting several instances of federal waste that were discovered under his leadership: $101 million for DEI contracts at the Department of Education, $59 million for illegal alien hotel rooms in New York City, $45 million for DEI scholarships in Burma, $42 million for social and behavioral change in Uganda, $20 million for Arab Sesame Street, and $8 million for making mice transgender. As a thank you, Trump presented Musk with a golden key to the White House. 6:40pm- Dr. Stanley Goldfarb—Chairman of Do No Harm & a Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania—joins The Rich Zeoli Show to discuss Penn Medicine's decision to stop performing sex-change surgeries on children. They will, however, continue to prescribe irreversible puberty blockers for children.

1 - Dom kicks off hour 2 with California's updated stance on a trans athlete competing in the women's state high school track meet. How are they going to divvy up the medals if this athlete places above the other competitors? What kind of message does this send to the rest of the field and athletes everywhere? 110 - Your calls. 120 - What is to be done about motorized bicycles and scooters after a child in Williambsurg was decked by a bike and hospitalized? Why don't they follow the rules of the road like cars? Why must pedestrians and motorists constantly battle with them? 130 - Should the Phillies retaliate against the Braves' Spencer Strider for plunking Bryce Harper? The debate ensues. 140 - Some breaking news regarding Penn Medicine! No more gender affirming care. Will CHOP follow suit? Your calls. 150 - Mikie Sherrill doesn't need a 20 million dollar to know what people need, because she “listens”. Will this be a good campaign strategy? Does Mayor Pete think porn will win male voters back? 155 - Is Harvard grossly miscalculating where they stand?

12 - What files should the FBI release first? The listeners speak out in Dom's latest poll. 1205 - Is the Epstein files bigger than the January 6th file? Is Dan Bongino telling the truth about it? Henry doesn't think so. 1215 - Side - good person who did a bad thing 1220 - More on the FBI and the cases that have great public interest. Is Kash Patel as buttoned up as Bongino is on this issue? 1230 - Dom continues on the validity of what Bongino and Patel are saying. 1235 - Whitemarsh resident Christine Balster joins us to celebrate the township reinstating their 4th of July parade. Which township leaders did not show up to their meeting last night, and does this suggest impropriety from them after all this? Why would the town not want to celebrate its own Revolutionary War heritage? 1240 - Your calls. 1250 - Finishing the hour with conspiracy… about mail-in voting! Your calls. 1 - Dom kicks off hour 2 with California's updated stance on a trans athlete competing in the women's state high school track meet. How are they going to divvy up the medals if this athlete places above the other competitors? What kind of message does this send to the rest of the field and athletes everywhere? 110 - Your calls. 120 - What is to be done about motorized bicycles and scooters after a child in Williambsurg was decked by a bike and hospitalized? Why don't they follow the rules of the road like cars? Why must pedestrians and motorists constantly battle with them? 130 - Should the Phillies retaliate against the Braves' Spencer Strider for plunking Bryce Harper? The debate ensues. 140 - Some breaking news regarding Penn Medicine! No more gender affirming care. Will CHOP follow suit? Your calls. 150 - Mikie Sherrill doesn't need a 20 million dollar to know what people need, because she “listens”. Will this be a good campaign strategy? Does Mayor Pete think porn will win male voters back? 155 - Is Harvard grossly miscalculating where they stand? 2 - Karoline Leavitt let the nation know where the Trump administration stands on the trade deficit. Did she sprint to the podium? Does Jasmine Crockett really think Trump would arrest her? 210 - We play a clip of a Sheriff confronting and arresting a man who threatened his life. The kicker? He's a Florida officer who went all the way out to Walla Walla, Washington to nab him! Then by surprise, Sheriff Mike Chitwood quickly joins us to give us the story. How did this whole ordeal start? How did Mike become a target? What steps can be taken to combat this online behavior? What is their local department doing differently from the rest? 225 - Dom thanks the listeners for rising up to save the Whitemarsh Township 4th of July parade. Your calls. 230 - Dom's Money Melody! 240 - Riley Gaines challenges Keith Olbermann to a race. Will he accept? 250 - The Lightning Round!

This episode features Alicia Gresham, Chief Medical Officer and Chief Physician at Penn Medicine. Alicia shares insights into the organization's strategic planning process, including how frontline team members are engaged to help identify new market opportunities. She discusses the evolving challenges in today's healthcare landscape, the ongoing shift toward outpatient care, and the implementation of employee education programs that support long-term transformation at Penn.

Depression, anxiety, and apathy are common symptoms that are often overlooked in people with Parkinson's disease (PD). Nearly half of those living with PD are likely to experience depression or anxiety at some point, but these non-motor symptoms often go unrecognized and undertreated. Because their signs can overlap and mimic one another, it can be challenging to pinpoint exactly what someone is going through. Depression is known for feelings of persistent sadness or hopelessness. Anxiety might look like constant worry, excessive nervousness, or getting upset easily. Apathy, which is sometimes mistaken for depression, is the lack of motivation or interest to do things you used to enjoy. These symptoms can greatly impact your quality of life and worsen other PD symptoms.  In this episode, we speak with Lauren Zelouf, MSW, LCSW from Penn Medicine's Parkinson's Disease & Movement Disorders Center, a Parkinson's Foundation Center of Excellence. She shares how to distinguish among these different symptoms, emphasizes the importance of recognizing the signs, and offers coping strategies for managing symptoms and seeking support. Follow and rate us on your favorite podcast platform to be notified when there's a new episode! Let us know what other topics you would like us to cover by visiting parkinson.org/feedback.

Tackling the labor shortage in science and medicine requires valuing healthcare as a noble profession and using technology to streamline training. In this episode, Kevin Mahoney, CEO of the University of Pennsylvania Health System, discusses the challenges of talent shortages amid a retiring baby boomer generation and a smaller incoming workforce, emphasizing the need for technology to fill the gap. He shares Penn Medicine's innovative initiatives, including flash radiation for cancer treatment and a startup providing maternal support, highlighting their commitment to both technological advancements and human connections. Kevin touches on the need to repair broken systems by speaking to the patients and fixing the issues, refocusing on clinical outcomes, and reimagining the delivery of care. He also underscores that embracing change management with intentionality is crucial for healthcare organizations. Tune in and learn how one of the nation's leading health systems is embracing bold strategies to improve healthcare delivery and workforce development! Resources: Connect with and follow Kevin Mahoney on LinkedIn. Discover more about Penn Medicine's University of Pennsylvania Health System on their LinkedIn and website.

In this episode, Scott Becker covers seven major healthcare stories, from layoffs at Washington Health System and Penn Medicine to policy changes, hospital consolidations, and leadership updates—including Dr. Mehmet Oz's CMS confirmation progress.

Become a mini geriatrician in our new Geriatrics series! Geriatricize your knowledge of caring for older adults with unintentional weight loss! You'll round out your history taking and weight gain plan by harnessing the age-friendly “5Ms”. We're joined by Dr. Eva Szymanski (@eva_szy), expert geriatrician at Penn Medicine. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Rapid fire questions Case Defining Unintentional Weight Loss Applying the Geriatric 5Ms Framework Diagnostic Work-Up Addressing Ageism in Medical Decisions Defining Geriatric Syndromes Weight Loss Treatments Outro Credits Producer: Leah Witt, MD, Rachel Miller, MD, MSEd Writers: Abigail Schmucker, MD, Joseph Young, MD, Margaret Heller, MD, Alyson Michener, MD, Leah Witt, MD Show Notes, Infographic and Cover Art: Leah Witt, MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Molly Heublein, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Eva Szymanski, MD Sponsor: Quince Upgrade your closet this year without the upgraded price tag. Go to Quince.com/curb for 365-day returns, plus free shipping on your order! Sponsor: Freed Visit Freed.ai and use code CURB50 to get $50 off your first month.  Sponsor: Mint Mobile Switch to Mint and new customers can get half off an Unlimited plan until February 2. To get your new wireless plan for just $15 a month, and get the plan shipped to your door for FREE, go to MINTMOBILE.com/curb

In this episode of The Brave Enough Show, Dr. Sasha Shillcutt and Dr. Lindsay Semler discuss:   The difference between Moral Distress versus Moral Injury and what it means to those of us in healthcare  How to process failure in our jobs and our lives  How to speak up even when you don't feel safe to do so.     Quote: “The majority of decisions we make every day in healthcare are ethical, moral decisions. They are the hard ones, and the ones where we must feel we have a voice.” Dr. Lindsay Semler      Guest Bio:  Dr. Lindsay Semler is the Executive Director of Clinical Ethics and Department of Medicine Faculty at Brigham and Women's Hospital, and a Lecturer at Harvard Medical School. She is also the Founder & President of Semler Ethics Consulting, LLC. Her background includes critical care and emergency nursing experience, as well as education, quality improvement, and leadership at UPMC and Penn Medicine. She was also the director of the system-wide Ethics program at INTEGRIS Health. Lindsay obtained her BSN and MSN from the University of Pittsburgh, Doctor of Nursing Practice degree with a focus on moral distress from Johns Hopkins, and the Advanced Training in Healthcare Ethics certificate from the University of Washington. She is certified as a Healthcare Ethics Consultant (HEC-C) and critical care nurse (CCRN). Her bioethical areas of interest focus on organizational and preventive healthcare ethics, addressing moral distress, and teaching future generations of healthcare providers.    Lindsay Semler, DNP, RN, CCRN, HEC-C   Executive Director | Ethics Service, Brigham and Women's Hospital  Co-Chair | Ethics Committee, Brigham and Women's Hospital  Faculty | Department of Medicine, Brigham and Women's Hospital  Lecturer | Harvard Medical School  Member | Center for Bioethics, Harvard Medical School  Founder & President | Semler Ethics Consulting https://semlerethicsconsulting.com           Episode Links:  REVIVE Retreat Brave Ballance   Follow Brave Enough:   WEBSITE | INSTAGRAM | FACEBOOK | TWITTER | LINKEDIN Join The Table, Brave Enough's community. The ONLY professional membership group that meets both the professional and personal needs of high-achieving women.